Microbiology and Immunology

Weill Cornell Medicine has received $4.2 million to study how the immune system in some people infected with HIV can keep the virus under control, which could lead to novel therapeutic strategies for thwarting or eliminating HIV.

A multinational team led by Weill Cornell Medicine investigators developed a test that will help measure the persistence of HIV in people affected by viral strains found predominantly in Africa—a vital tool in the search for an HIV cure that will benefit patients around the world.

A new consortium co-led by Weill Cornell Medicine, has been awarded a five-year, $31 million grant from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases to accelerate the development of faster, more effective treatment regimens for tuberculosis (TB).

Dr. Carl Nathan, chair of the department of microbiology and immunology and the R.A. Rees Pritchett Professor of Microbiology at Weill Cornell Medicine, answers questions about interferon-γ's history and future.

Structural insights into a potent antimalarial drug candidate’s interaction with the malaria parasite Plasmodium falciparum have paved the way for drug-resistant malaria therapies, according to a new study by researchers at Weill Cornell Medicine and Van Andel Institute.

Weill Cornell Medicine researchers and the TB Drug Accelerator have received two grants totaling $6.8 million from the Bill & Melinda Gates Foundation to study tuberculosis (TB) drug development.

A key developmental step in the lifecycle of the most virulent species of malaria parasite, Plasmodium falciparum, depends in part on a series of molecular signals that are detailed in a new study led by researchers at Weill Cornell Medicine.

A typical gut bacterium that can spread through the body and cause a serious infection resists natural immune defenses and antibiotics by enhancing its protective outer layer, known as the cell envelope, according to a new study by Weill Cornell Medicine investigators. 

Small proteins, called chemokines, that direct immune cells toward sites of infection can also form DNA-bound nanoparticles that can induce chronic, dysfunctional immune responses, according to a new study by researchers at Weill Cornell Medicine and Hospital for Special Surgery (HSS).

Immunotherapy unleashes the power of the immune system to fight cancer. However, for some patients, immunotherapy doesn’t work, and new research may help explain why. 

Weill Cornell Medicine researchers have identified a protein in Mycobacterium tuberculosis (Mtb) that contributes to drug tolerance, a phenomenon that allows bacteria to survive treatment with drugs that would normally kill them.

A finding from Weill Cornell Medicine researchers sheds new light on the transmission of malaria, one of the biggest global public health challenges, which kills a young child every two minutes – more than any other infectious disease.

Mycobacterium tuberculosis (Mtb), the hardy bacterial species that causes tuberculosis (TB), has an unexpected vulnerability that future drugs may be able to exploit.

Tuberculosis (TB) is a wily old killer, one of the deadliest infectious diseases in history and one of the few that naturally infects only humans.

A better understanding of the biology of tuberculosis (TB) infection and improved drug combinations for the disease are two areas of research in which the TB Drug Accelerator (TBDA) has made strides since its inception a decade ago.

Researchers at Weill Cornell Medicine have gleaned new insights on the ways cells maintain the tips of their chromosomes, or telomeres. The findings help illuminate a wide range of phenomena, from cancer development to fungal evolution.

Ovarian tumors can be made more sensitive to immunotherapy by blocking the recruitment of certain cells to the...

The COVID-19 pandemic is a striking reminder that viruses scorn borders.

Trained in TB research, Pakistani native Dr. Omar Vandal, Ph.D. ’07, now oversees Gates Foundation grants that save lives worldwide.

An investigation by Weill Cornell Medicine scientists has yielded two breakthroughs in the pursuit of combating growing resistance to tuberculosis treatments.